Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder

Journal of Clinical Psychopharmacology

Volumn 32, Issue 6, 2012, Pages 814-819

  Miller, Shefali ^a   Ittasakul, Pichai ^b   Wang, Po W ^a   Hill, Shelley J ^a   Childers, Meredith E ^a   Rasgon, Natalie ^a   Ketter, Terence A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

bipolar disorder; effectiveness; obesity; treatment; ziprasidone

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTPATIENT CARE; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OBESITY; PIPERAZINES; THIAZOLES; TREATMENT OUTCOME;

EID: 84870253681     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318270dea9     Document Type: Article

References (22)

1. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64:543-552. (Pubitemid 46718287)
2. Ketter TA. Handbook of Diagnosis and Treatment of Bipolar Disorder. Washington, DC: American Psychiatric Publishing, Inc.; 2010.
3. Keck PE Jr, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry. 2003;64:1426-1435. (Pubitemid 41270100)
4. Calkin C, van de Velde C, Ruzickova M, et al. Can body mass index help predict outcome in patients with bipolar disorder? Bipolar Disord. 2009;11:650-656.
5. Fagiolini A, Kupfer DJ, Houck PR, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;160:112-117. (Pubitemid 36042434)
6. Kemp DE, Gao K, Chan PK, et al. Medical comorbidity in bipolar disorder: Relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord. 2010;12:404-413.
7. Ketter TA, Citrome L, Wang PW, et al. Treatments for bipolar disorder: Can number needed to treat/harm help inform clinical decisions? Acta Psychiatr Scand. 2011;123:175-189.
8. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160:741-748. (Pubitemid 41079608)
9. Potkin SG, Keck PE Jr, Segal S, et al. Ziprasidone in acute bipolar mania: A 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005;25:301-310. (Pubitemid 41065070)
10. Bowden CL, Vieta E, Ice KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: A 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry. 2010;71: 130-137.
11. Citrome L, Reist C, Palmer L, et al. Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder. Schizophr Res. 2009;115:115-120.
12. Keck PE Jr, Versiani M, Warrington L, et al. Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania. J Clin Psychiatry. 2009;70:844-851.
13. Weiden PJ, Daniel DG, Simpson G, et al. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23:595-600. (Pubitemid 37443191)
14. Morrato EH, Cuffel B, Newcomer JW, et al. Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients. J Clin Psychopharmacol. 2009; 29:26-32.
15. Sachs GS, Thase ME, OttoMW, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2003;53:1028-1042. (Pubitemid 36645233)
16. Sachs GS, Guille C, McMurrich SL. A clinical monitoring form for mood disorders. Bipolar Disord. 2002;4:323-327.
17. Dennehy EB, Bauer MS, Perlis RH, et al. Concordance with treatment guidelines for bipolar disorder: Data from the systematic treatment enhancement program for bipolar disorder. Psychopharmacol Bull. 2007;40:72-84.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington: American Psychiatric Association; 2000.
19. Wang PW, Hill SJ, Childers ME, et al. Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients. J Psychiatr Res. 2011;45:1128-1132.
20. Goldberg JF, Brooks JO 3rd, Kurita K, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: Findings from the STEP-BD. J Clin Psychiatry. 2009;70:155-162.
21. Post RM, Altshuler LL, Frye MA, et al. Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. J Clin Psychiatry. 2010;71:1176-1186.
22. Bowden CL. The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder. Neuropsychiatr Dis Treat. 2011;7:87-92.